Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1435-1441

  Shapiro, Charles L ^a   Ervin, T ^a   Welles, L ^a   Azarnia, N ^a   Keating, J ^a   Hayes, Daniel F ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EVACET; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; ENCAPSULATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

EID: 0032945306     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1435     Document Type: Article

References (39)

1. Balazovits JEA, Mayer LD, Bally MB, et al: Analysis of the effect of liposome encapsulation on the vesicant properties, acute cardiac toxicity, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23:81-86, 1989
2. Kanter PM, Bullard GA, Ginsburg RA, et al: Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 7:17-26, 1993
3. Kanter PM, Bullard GA, Pilkiewicz FG, et al: Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 7:85-95, 1993
4. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary Phase I studies. J Clin Oncol 7:1777-1785, 1995
5. Muggia FM, Hainsworth JD. Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 3:987-993, 1997
6. Batist G, Ahlgren P, Panasci L, et al: Phase II study of liposomal doxorubicin (TLCTLC D-99) in metastatic breast cancer. Proc Am Soc Clin Oncol 11:82, 1992 (abstr)
7. TLC D-99 [drug information packet]. Princeton, NJ, The Liposome Company, 1997
8. Fonseca GA, Valero V, Buzdar A, et al: Phase II study of TLC D-99 (liposomal doxorubicin) in patients with metastatic breast carcinoma. Proc Am Soc Clin Oncol 14:95, 1995 (abstr)
9. Fonseca GA, Valero V, Buzdar A, et al: Decreased cardiac toxicity by TLC D-99 (liposomal doxorubicin) in the treatment of metastatic breast carcinoma. Proc Am Soc Clin Oncol 14:96, 1995 (abstr)
10. O'Day SJ, Mazanet R, Skarin AT, et al: Dose escalation of liposome-encapsulated doxorubicin (TLC D-99) with granulocyte colony stimulating factor (G-CSF) support in patients with advanced malignancies. Proc Am Soc Clin Oncol 13:406, 1994 (abstr)
11. Jones RB, Holland JF, Bhardwaj S, et al: A Phase I-II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5:172-177, 1987
12. Bronchud MH, Howell A, Crowther D. et al: The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121-125, 1989
13. Torti FM, Bristow MF, Howes AE, et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule, assessment by endomyocardial biopsy. Ann Intern Med 99:745-749, 1983
14. Ewer MS, Ali MK, Mackay B. et al: A comparison of cardiac biopsy grades and ejection fraction estimation in patients receiving Adriamycin. J Clin Oncol 5:112-117, 1984
15. Batist G, Winer E, Navari R, et al: Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs. doxorubicin in a randomized trial of metastatic breast carcinoma. Proc Am Soc Clin Oncol 17:1717, 1998 (abstr)
16. Harris L. Winer E, Batist G, et al: Phase in study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin in patients with metastatic breast carcinoma. Proc Am Soc Clin Oncol 17:1512, 1998 (abstr)
17. Henderson IC, Allegra JC. Woodcock T, et al: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 5:560-571, 1989
18. Sledge GW Jr, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial. Proc Am Soc Clin Oncol 16:2, 1997
19. Paridaens R. Bruning P, Klijn J, et al: An EORTC crossover trial comparing single-agent taxol and doxorubicin as first-and second-line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 16:539, 1997 (abstr)
20. Chan S, Friedrichs K, Noel D, et al: A randomized Phase III study of taxotere versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating-containing regimen: Preliminary results. Proc Am Soc Clin Oncol 16:540, 1997 (abstr)
21. Basser RL, Green MD: Complications of treatments: Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 19:57-77, 1995
22. Gabizon AA: Liposomal anthracyclines. Hematol Oncol Clin North Am 2:431-450, 1994
23. Rahman A, Carmichael D, Harris M. et al: Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 46:2295-2299, 1986
24. Mayer LD, Tai LCL, Ko DSC, et al: Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49:5922-5930, 1989
25. Sugarman SM, Perez-Soler R: Liposomes in the treatment of malignancy: A clinical perspective. Clin Rev Oncol Hematol 12:231-242, 1992
26. Shan K, Lincoff AM, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58, 1996
27. Alexander J, Dainiak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278-283, 1979
28. Piver MS, Marchetti DL, Parthasarathy KL, et al: Doxorubicin hydrochloride (adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer 56:76-80, 1985
29. Schwartz RG, McKenzie WB, Alexander J, et al: Congestive Heart Failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 82:1109-1118, 1987
30. McKillop JH, Bristow MR, Goris ML, et al: Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106:1048-1056, 1983
31. Druck MN, Gulenchyn KY, Evans W. et al: Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiac toxicity. Cancer 53:1667-1674, 1984
32. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91-710-717, 1979
33. Casper ES, Schwanz GK, Sugarman A, et al: Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 5:2111-2117, 1997
34. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1145, 1996
35. Wood WC, Budman DR, Kozun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II node-positive breast carcinoma. N Engl J Med 330:1253-1257, 1994
36. The French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil cyclophosphamide and epirubicin regimens differing in epirubicin dose in advanced breast cancer. J Clin Oncol 9:305-312, 1991
37. Focan C, Andrien JM, Closon MT, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
38. Marschner N, Kreienberg R, Souchon R, et al: Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Semin Oncol 21:10-15, 1994
39. Henderson IC, Berry D, Demitri G, et al: Improved disease-free (dfs) and overall survival (OS) from the addition of sequential paclitaxel (T) but from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:390A, 1998 (abstr)